Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NEO 201

Next Previous
Drug Profile

NEO 201

Alternative Names: 16C3 antibody; h16C3 monoclonal antibody; NEO-201

Latest Information Update: 24 Jul 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Precision Biologics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; Natural killer cell stimulants; Regulatory T-lymphocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cervical cancer; Head and neck cancer; Non-small cell lung cancer; Uterine cancer
  • Phase I Solid tumours
  • Preclinical Gynaecological cancer

Most Recent Events

  • 22 Jul 2024 NEO 201 is still in phase I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) in USA (IV) (NCT03476681)
  • 16 Jul 2024 Precision Biologics has patent protection for NEO 201 in US
  • 30 May 2024 Efficacy data from a phase I/II trial in Non-small cell lung cancer, Head and neck cancer, Uterine cancer and Cervical cancer released by Precision Biologics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top